Abilify vs Rexulti
Side-by-side cost comparison based on Medicare Part D data
Abilify
Aripiprazole
Manufactured by Otsuka/BMS
Rexulti
Brexpiprazole
Manufactured by Otsuka
Abilify costs 89% less per claim than Rexulti ($45.00 vs $396.00). A generic version of Abilify is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Abilify | Rexulti |
|---|---|---|
| Avg Cost Per Claim | $45.00 | $396.00 |
| Total Medicare Spending | $567.0M | $1.2B |
| Total Beneficiaries | 1,680,000 | 356,000 |
| Total Claims | 12,480,000 | 3,120,000 |
| Annual Cost/Patient | $338.00 | $3,466.00 |
| Year-over-Year Change | -38.4% | +22.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Otsuka/BMS | Otsuka |
| Condition | Mental Health | Mental Health |
| Generic Name | Aripiprazole | Brexpiprazole |
Abilify vs Rexulti: What the Data Shows
Abilify (Aripiprazole) and Rexulti (Brexpiprazole) are both used to treat mental health. Based on Medicare Part D data, Abilify costs $45.00 per claim, which is 89% less than Rexulti at $396.00 per claim.
Medicare spent $567.0M on Abilify and $1.2B on Rexulti. In terms of patient reach, Abilify serves more beneficiaries (1,680,000 vs 356,000).
Year-over-year spending changed -38.4% for Abilify and +22.4% for Rexulti. Rexulti saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Abilify is cheaper at $45.00 per claim, compared to $396.00 for Rexulti. That makes Abilify about 89% less expensive per claim based on Medicare Part D data.
Yes, both Abilify and Rexulti are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Aripiprazole and generic Brexpiprazole can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Abilify covering 1,680,000 beneficiaries, and $1.2B on Rexulti covering 356,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.